Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Diabetes Sci Technol ; : 19322968231174040, 2023 May 10.
Article in English | MEDLINE | ID: mdl-37162092

ABSTRACT

Diabetes is the leading cause of chronic kidney disease (CKD) and end-stage kidney disease in the world. It is known that maintaining optimal glycemic control can slow the progression of CKD. However, the failing kidney impacts glucose and insulin metabolism and contributes to increased glucose variability. Conventional methods of insulin delivery are not well equipped to adapt to this increased glycemic lability. Automated insulin delivery (AID) has been established as an effective treatment in patients with type 1 diabetes mellitus, and there is emerging evidence for their use in type 2 diabetes mellitus. However, few studies have examined their role in diabetes with concurrent advanced CKD. We discuss the potential benefits and challenges of AID use in patients with diabetes and advanced CKD, including those on dialysis.

2.
Nephrology (Carlton) ; 14(2): 148-54, 2009 Apr.
Article in English | MEDLINE | ID: mdl-19076292

ABSTRACT

AIM: To determine if levels of coated-platelets, which are potentially pro-thrombotic, are increased in end-stage renal disease patients on haemodialysis, a condition associated with high cardiovascular disease risk. METHODS: In a cross-sectional observational study, coated-platelet levels were measured by flow cytometry in 25 end-stage renal failure haemodialysis patients and 25 controls without renal disease. Associations between coated-platelet levels and clinical and biochemical factors relevant to renal and cardiovascular disease were evaluated. RESULTS: Mean +/- SD coated-platelet levels were higher in the dialysis group than in the control group (39.3+/-14.3% vs 30.9+/-10.3%, P=0.02). The number of subjects with high coated-platelet levels (>40%) was larger in the dialysis than in the control group (13/25 vs 4/25, chi(2) test, P=0.007). On univariate analysis, coated-platelet levels correlated with serum C-reactive protein levels in renal failure (r=0.47, P=0.02) and inversely with white cell count in the control group (r= -0.60, P=0.001). Coated-platelet levels were higher in dialysis patients reporting alcohol abstinence than among those reporting 'social' drinking (44.3+/-12.6 vs 28.8+/-13.5%, P=0.01). Age, gender, body weight, smoking, diabetes, lipid levels and lipid-lowering drugs were not associated with coated-platelet levels (all P>0.05). CONCLUSION: Coated-platelet levels are increased in haemodialysis patients relative to subjects with normal renal function, and are related to inflammation and alcohol abstinence. Other vascular risk factors, such as smoking, lipids and diabetes, were not related to coated-platelet levels. Coated-platelets may be implicated in the increased thrombosis and vascular risk in end-stage renal disease.


Subject(s)
Kidney Failure, Chronic/blood , Platelet Count , Renal Dialysis , Aged , C-Reactive Protein/analysis , Cross-Sectional Studies , Erythropoietin/therapeutic use , Female , Humans , Kidney Failure, Chronic/complications , Male , Middle Aged , Thrombosis/etiology
3.
Pathology ; 34(2): 138-43, 2002 Apr.
Article in English | MEDLINE | ID: mdl-12009095

ABSTRACT

AIMS: The reported association of glomerular disease with chronic lymphocytic leukaemia (CLL) is rare despite the relative frequency of this type of leukaemia. Hence, we have examined the renal biopsies in three patients with CLL and glomerulonephritis. METHODS: Renal biopsies were examined by light microscopy, immunofluorescence microscopy and electron microscopy. RESULTS: One of two patients with mild impairment of renal function and an active urinary sediment had ultrastructural features of idiopathic type I membranoproliferative glomerulonephritis (MPGN), and the other had features of fibrillary/ immunotactoid glomerulonephritis with deposits of IgG and C3. One patient with nephrotic syndrome had characteristic electron microscopic appearances of type III MPGN. In all three there was an association with monoclonal gammopathy. The parameters of glomerular damage improved in association with response to drug treatment of the CLL. CONCLUSION: There is a spectrum of types of MPGN seen in patients with CLL and there appears to be an association with the presence of monoclonal gammopathy. This is the first reported case of type III MPGN in CLL.


Subject(s)
Glomerulonephritis, Membranoproliferative/pathology , Kidney Glomerulus/pathology , Leukemia, Lymphocytic, Chronic, B-Cell/pathology , Vidarabine/analogs & derivatives , Adult , Aged , Antineoplastic Agents/therapeutic use , Chlorambucil/therapeutic use , Drug Therapy, Combination , Female , Glomerular Mesangium/ultrastructure , Glomerulonephritis, Membranoproliferative/complications , Glomerulonephritis, Membranoproliferative/drug therapy , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/complications , Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy , Male , Microscopy, Fluorescence , Middle Aged , Paraproteinemias/complications , Paraproteinemias/drug therapy , Paraproteinemias/pathology , Prednisolone/therapeutic use , Treatment Outcome , Vidarabine/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...